Challenges of Treating Acute Coronary Syndrome

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this video, from AJMCtv, Peter Berger, MD, FACC, FAHA, chairman of cardiology and co-director of the Geisinger Heart & Vascular Institute and director of the Cardiovascular Center for Clinical Research at Geisinger Clinic in Danville, Pennsylvania, discusses the challenge of individualizing antiplatelet treatment for acute coronary syndrome (ACS) patients.

Related Articles
Many cardiologists and pharmacists are concerned about clopidogrel, especially when it is prescribed for patients with diabetes.
For the first time, one antiplatelet agent has been recommended over another for non–ST-segment elevation acute coronary syndrome.
Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.
Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study.
Latest Issues
$auto_registration$